The present invention relates in one aspect to the discovery of novel mesoporous silica nanoparticles (MSNs) templated around and comprising benzalkonium chloride (BAC). In certain embodiments, the BAC-SiO.sub.2 mesoporous nanoparticles are capable of sustained release of BAC under acidic conditions, thereby acting as a long release antimicrobial agent. In other embodiments, the BAC-SiO.sub.2 mesoporous nanoparticles can be incorporated into a variety of consumer products as an antimicrobial agent additive, including for example, but not limited to, surgical dressings, bandages, deodorants, soaps, facial cleansers and industrial cleaners.

The present invention relates in one aspect to the discovery of novel mesoporous silica nanoparticles (MSNs) templated around and comprising benzalkonium chloride (BAC). In certain embodiments, the BAC-SiO.sub.2 mesoporous nanoparticles are capable of sustained release of BAC under acidic conditions, thereby acting as a long release antimicrobial agent. In other embodiments, the BAC-SiO.sub.2 mesoporous nanoparticles can be incorporated into a variety of consumer products as an antimicrobial agent additive, including for example, but not limited to, surgical dressings, bandages, deodorants, soaps, facial cleansers and industrial cleaners.

Invention deals with a macular carotenoid formulation comprising Carotenoids, Lutein, Zeaxanthin, Meso Zeaxanthin, Beta Carotene, Alpha Carotene, Lycopene and Cryptoxanthin in a synergistic combination. The formulation helps in increasing macular pigment optical density (MPOD) related to prevention of age-related macular degeneration (ARMD). The formulation is used as a nutrient, nutraceutical or dietary supplement. The dietary supplement may be formulated as soft gel capsules, two-piece hard-shell capsules, liquid-fill capsules, tablets, effervescent granules, gummies, powder mixes, stick packs, beverages, emulsions, bakery products, dairy products, tinctures, oil suspensions, bead-lets, powders, cold water-soluble powders, emulsions and granules or any combination thereof. The present invention can be used for the development of functional food, dietary plan and as a nutritional supplement. In exemplary embodiment, formulation is available in forms like oil suspension, beadlets, powders, cold water-soluble powders, emulsions and granules.

The described invention provides a method of treating localized pain comprising (a) applying topically to an area of skin of a subject overlaying the localized pain a pharmaceutical composition comprising a cannabinoid component and a chemical driver component comprising two or more of methylsulfonylmethane (MSM), and ethoxydiglycol, and propylene glycol; and applying an external energy effective to enhance transdermal permeation of the pharmaceutical composition into the skin. wherein the components of the composition and the device are cooperatively effective to work together to maximize transdermal delivery of the composition, deeply penetrate the skin of the subject and to provide pain relief.

The described invention provides a method of treating localized pain comprising (a) applying topically to an area of skin of a subject overlaying the localized pain a pharmaceutical composition comprising a cannabinoid component and a chemical driver component comprising two or more of methylsulfonylmethane (MSM), and ethoxydiglycol, and propylene glycol; and applying an external energy effective to enhance transdermal permeation of the pharmaceutical composition into the skin. wherein the components of the composition and the device are cooperatively effective to work together to maximize transdermal delivery of the composition, deeply penetrate the skin of the subject and to provide pain relief.

The present invention provides a photosensitising composition comprising a mixture of: at least one surfactant; at least one alcohol; and/or water, with the proviso that when the at least one surfactant is an alcohol, it is different from the at least one alcohol. In particular, the composition may comprise a mixture of glycerol, ethanol and water. Alternatively, the composition may comprise a mixture of polyethylene glycol, ethanol and water. The photosensitising composition may further comprise at least one photosensitising compound. The present invention also provides a method of treating and/or preventing conditions caused by microorganisms in a subject.

The present invention provides a photosensitising composition comprising a mixture of: at least one surfactant; at least one alcohol; and/or water, with the proviso that when the at least one surfactant is an alcohol, it is different from the at least one alcohol. In particular, the composition may comprise a mixture of glycerol, ethanol and water. Alternatively, the composition may comprise a mixture of polyethylene glycol, ethanol and water. The photosensitising composition may further comprise at least one photosensitising compound. The present invention also provides a method of treating and/or preventing conditions caused by microorganisms in a subject.

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.

The present invention relates to a compound represented by the formula (I) or a salt thereof.

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.

The present invention relates to a compound represented by the formula (I) or a salt thereof.

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof.

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.